eurofins q1 2020 results

Western Europe remains the largest region for Eurofins, representing c.49% of total Group revenues in Q1 2019, with France generating 20% of total Group revenues, ahead of Germany which accounted for 10% of total Group revenues, whilst Benelux, the UK & Ireland, and the Nordic countries each contributed ca.6% to Q1 2019 revenues. In September 2020, Eurofins Diatherix continued to leverage its extensive respiratory and infectious disease expertise with the launch of Flu Plus, a new test to identify SARS-CoV-2 and five additional and most prevalent viruses associated with respiratory illnesses. Many of Eurofins’ core businesses (excluding COVID-19 clinical reagents and testing) already grew organically well over 5% in Q3 2020 in all business lines (Environment, Food and BioPharma Product testing in particular). Results are reviewed by a licensed physician and provided via email within 24 hours of sample receipt. Eurofins Raises Its 2020 Objectives After Strong Momentum in Its Core Business, as Well as in COVID-19 Related Activities in October and November PRESS RELEASE Businesswire Dec. 15, 2020… On the other hand, in South America, Food and Environment testing services remained in negative territory in NM 2020, even if slowly recovering in Q3 2020. Q1 2020 Results Results per business units 7 Volumes have increased by 31% in the Spain BU, in which the total growth of the olive oil market was 19%. CCC co-developed, in close co-operation with Nestlé Research (Lausanne, Switzerland), this novel method and managed the necessary collaborative study to fulfil the specific official standard method performance requirements. Quarterly Statement Q1 2020 Results May 12, 2020. The core business (excluding COVID-19 clinical reagents and testing revenues) recovered to small positive organic growth in Q3 2020 whilst we saw strong demand for COVID-19 testing. Fastly released their Q1 2020 earnings report on May 6. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and a very large range of testing methods. In October 2020, Eurofins U.S. Clinical Diagnostics announced the launch of its Eurofins At-Home COVID-19 Nasal PCR Test. Beyond 2022, Eurofins sees a strong outlook for its core Biopharma, Food, Genetic, Cosmetic, Environment and advanced esoteric Clinical testing activities. The I’screen AFLA M1 milk testing kit is the first screening method to receive AOAC approval for aflatoxin M1 analysis in milk commodities. Eurofins will hold a conference call with analysts and investors today at 15:00 pm CET to discuss the results and the performance of Eurofins, as well as its outlook, and will be followed by a questions and answers (Q&A) session. Over the first nine months of 2020 (NM 2020), revenues grew 12.0% to EUR 3,736m vs. EUR 3,335m during the same period last year. Contact Us |  U.S. +1 8335 268 347 In October 2020, Eurofins launched Europe’s first validated test method to evaluate filtration capacity of masks for SARS-CoV-2. Beyond this, Eurofins plans to keep a conservative balance sheet, its long-term oriented funding strategy and to retain its Investment Grade credit rating as well as above industry average ESG ratings. •Q1 2020 revenues increased 7% year-on-year to EUR 1,142m • 4.1% organic growth (4.6% excluding Boston Heart Diagnostics & two laboratories closed due to a fire), showing the resilience of Eurofins underlying markets • Negative impact recorded in Q1 2020 from lockdown measures (China, Europe, USA) not yet compensated by additional COVID-19 testing and research activities EUR 20 million from its insurers in October 2020 to compensate for the lost gross margin resulting from the 02 June 2019 cyber-attack, bringing the total proceeds received to date to ca. In spite of the continued COVID-19 pandemic related business disruptions, Eurofins core business (excluding any COVID-19 clinical testing and reagents revenues) returned to small positive organic growth in Q3 2020, once again demonstrating the strong resilience of Eurofins’ end markets. This innovation should go a long way towards making sensitive PCR testing available more broadly by alleviating sampling personnel bottlenecks. As one of the most innovative and quality-oriented international groups in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities and healthcare practitioners around the world. Q1 2020 Results May 12, 2020. In addition, Eurofins is one of the leading global emerging players in esoteric and molecular clinical diagnostic testing. Q3 2020 revenues increased 21.0% year-on-year to EUR 1,413m vs. EUR 1,167m in Q3 2019. Investor Relations Webcast. A The 2020 FCFF objective of EUR 500m was introduced in March 2020, but adjusted to EUR 600m in H1 2020 to include the IFRS 16 related reclassification. The Group’s objective is to provide its customers with high-quality and innovative services, accurate results on time and, when requested, expert advice by its highly-qualified staff. From any device, click the link above to join the conference call. A business will generally be considered mature when: i) The Group’s systems, structure and processes have been deployed; ii) It has been audited, accredited and qualified and used by the relevant regulatory bodies and the targeted client base; iii) It no longer requires above-average annual capital expenditures, exceptional restructuring or abnormally large costs with respect to current revenues for deploying new Group IT systems. Press |  Investors, Sitemap | In September 2020, Eurofins Technologies announced that its ELISA assay (enzyme-linked immunosorbent assay) for the detection of aflatoxin M1, I’screen AFLA M1 milk, has been granted AOAC Research Institute Performance Tested MethodsSM status (AOAC Cert. Eurofins has received an additional ca. These objectives reflect the continuation of a strong focus on margins and cash flow generation, which has not been derailed by the COVID-19 related activities as these are at or above Group margin and as Eurofins’ 5 years programme to build a world-class fully digitalised hub and spoke laboratory network will be completed soon. Receiving the AOAC Performance Tested MethodsSM status demonstrates Eurofins Technologies’ commitment to providing high quality test methods for its food safety customers. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantees can be made as to their completeness or validity. Agenda –Q3/NM 2020 Results Presentation. Many of Eurofins’ core businesses across Food, Environment and BioPharma testing achieved more than 5% organic growth in Q3 2020. Although Eurofins exposure to clinical testing and IVD products is recent (it only started in 2014) and small (under 20% of Group revenues in 2019), cooperation with other Group companies enabled an outsized impact on overall Group results in Q3. Eurofins Scientific SE … This press release contains forward-looking statements and estimates that involve risks and uncertainties. China 10% China 6% Rest of World 7% Europe 24% Automotive 63% Racing 28% Applied 10% Group Q1 2020 revenues £109m (Q1 2019 £284m) Q1 2020 LTM EBITDA £75m (Q1 2019 £150m) Automotive 2020 Half Year Results 06 August 2020 Eurofins reports solid growth of revenues, profits and cash flows in H1 2020 and continued positive organic growth in Q2 in spite of the COVID-19 pandemic. Some of the many developments that have taken place since the Group reported its H1 2020 results are highlighted below. E-mail: ir@eurofins.com, In September 2020, Eurofins Diatherix continued to leverage its extensive respiratory and infectious disease expertise with the launch of. Fructans, including inulin and fructo-oligosaccharides (FOS), are added as ingredients to all kinds of food, feed and pet food products. Q1 actuals were comfortably above estimates for revenue and profitability. No. Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Most core businesses saw a rebound in the course of Q3 2020 even though demand remained weaker in some areas (e.g. October and November 2020 trading performance has been strong. Eurofins Textile Testing Spain is currently the only laboratory in Europe and one of only three laboratories in the world to offer such a test, which is mandatory for all masks sold in the North American market. The list of entities classified as mature is reviewed at the beginning of each year and is relevant for the whole year. Growth compares full quarter in Q1 2020 vs partial quarter in Q1 2019 Q1 that only includes Sobi sales from 23 January, the date of acquisition. Results are provided via email within 24 hours of sample receipt. This is a major milestone in facilitating access to a very sensitive test as sampling by healthcare professionals is often a bottleneck to access gold standard PCR testing. Environment testing was more contrasted as some areas saw high single digit revenue performance in NM 2020 whilst others were still down. Eurofins Scientific SE In October 2020, following the recommendations from French health authorities to help combat the second wave of the COVID-19 pandemic, and in order to respond to increased testing demand, Eurofins Biomnis announced it was creating additional capacity of 15,000 tests per day carried out within 24 hours. More information can be found in the “COVID-19 related business developments” section of this release and at: Given the impossibility to predict the evolution of the COVID-19 pandemic in 2020 and 2021, the Group has decided to leave its objectives for those two years unchanged (2020-2021 objectives were set before the onset of the COVID-19 pandemic). In August 2020, Eurofins became the market leader in non-invasive prenatal testing (NIPT) in Japan with the acquisition of GeneTech Inc., a leading player in genetic analysis in Japan with over EUR 10 million revenues in 2019. No need to dial in. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific’s management as of the date of this release. By geography, Eurofins’ organic growth for Q1 2020 was 2.0% in Europe, 7.1% in North America and 4.6% in the Rest of the World, reflecting the different timings of … Following the recent successful refinancing of the Schuldschein loans maturing in July 2022, Eurofins has extended the average life of its senior debt instruments from 3.3 years to 4.1 years. A The 2020 FCFF objective of EUR 500m was introduced in March 2020, but adjusted to EUR 600m in H1 2020 to include the IFRS 16 related reclassification. 2020 vs. EUR 115m in H1 2019) as Eurofins acquired only seven companies in H1 2020, most of them in Q1 as part of discussions initiated prior to the pandemic spreading to Europe and North America. With over 50,000 staff across a network of more than 900 independent companies in over 50 countries generally specialised by end client markets and operating more than 800 laboratories, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services. The FDA EUA-authorised, self-collection kit gives consumers a painless, convenient and quick option to detect the virus from the comfort of their home. Q2 projections and full year raise were even more impressive. Fructans are mandatory components in infant formula and adult nutritionals and they are strictly regulated by various authorities worldwide. In September 2020, Eurofins became the market leader in environment testing in Taiwan with the acquisition of the SunDream Group, the second largest player in the market employing over 350 staff. On the other hand, non COVID-19 clinical testing volumes greatly suffered from the pandemic before rebounding in the summer. Q4 / FY 2019 Preliminary Results PRESENTATION Preliminary Q4 & FY 2019 Results Feb 10, 2020… Indeed the pandemic may well have a positive impact on the growth of Eurofins markets over the medium-term. Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP). • Q1 2020 revenues increased 7% year-on-year to EUR 1,142m • 4.1% organic growth ( 4.6% excluding Boston Heart Diagnostics & two laboratories closed due to a fire), showing the resilience of Eurofins underlying markets LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Comments from the CEO, Dr. Gilles Martin: “Q3 2020 was a positive quarter for Eurofins as the Group companies’ agility and speed of innovation enabled it to deliver very strong organic growth in spite of the pandemic. Eurofins also launched highly specific serology testing kits to be used by state or private laboratories on most open ELISA systems and expects to reach a production capacity of over 10 million tests per month by end May 2020. For fiscal 2020, the drug manufacturer lifted its 2020 GAAP EPS outlook, while reaffirmed the non-GAAP EPS target. The test can be used to evaluate the efficacy and safety of surgical masks and hygienic masks against COVID-19. Whilst many of Eurofins employees and other resources have been focused on and allocated to developing COVID-19 testing solutions and capacity in record time since March 2020, the Group has at the same time continued to make progress towards building a unique global network of fully digitalised state-of-the-art laboratories, market leadership positions, scale and scientific excellence to offer even better, faster, more cost effective and innovative services to its clients in other parts of the business. Our financial performance is concrete evidence of our positioning in attractive end markets as well as the results of years of investments to build a global network of state-of-the art laboratories and leading R&D teams which has enabled us to mobilise quickly and develop solutions to support healthcare authorities and our clients fighting the pandemic. In North America, revenues expanded 9.3% in NM 2020 as the BioPharma services business line grew high single digit and the Food testing activities showed resilience with organic growth close to 5% in NM 2020 whilst Environment testing remains in negative territory, in line with the market. Q1 2020: Strong start to year despite challenging period 1. Eurofins Textile Testing Spain is currently the only laboratory in Europe and one of only three laboratories in the world to offer such a test, which is mandatory for all masks sold in the North American market. Eurofins Scientific is an international life sciences company which provides a unique range of analytical testing services to clients across multiple industries. Eurofins Lancaster Laboratories Environmental (TALS) | Archive Eurofins Lancaster Laboratories Environmental Data Access (Data reported prior to May 2020) Eurofins Air Toxics Eurofins … Fructans, including inulin and fructo-oligosaccharides (FOS), are added as ingredients to all kinds of food, feed and pet food products. Revenues in Europe expanded by 15.2% in NM 2020 driven by strong performance in a number of business lines, including BioPharma and Agroscience testing services, which both grew high single digit across Europe. In routine Clinical Diagnostics, which is mostly based in France and to a lesser extent Spain, Germany and Benelux, the business saw very strong demand for COVID-19 tests, most notably PCR tests as well as IVD solutions. It is therefore now confirmed that Eurofins will significantly exceed its financial objectives for 2020 (which were set on 4 March 2020, before the COVID-19 disruptions started in Europe and North America and had remained unchanged since). Eurofins scientists develop multiple new solutions to support the world’s fight against the COVID-19 pandemic – ramping up production to enable over 20 million patients tests per month by end May 2020 Activity shows strong resilience in Q1 2020 – April 28, 2020. This assumes that the pandemic has been brought under control by then, underlying markets, including food service, hospitality and travel recover to historical levels and sampling and clinical research activities can resume as normal, by early 2022 and no COVID-19 clinical reagents and testing revenues in 2022 (objectives set at constant FX rates as of 30/09/2020). On 16 October 2020, Eurofins announced that its board of directors is proposing a ten-for-one stock split at the extraordinary general meeting to be held on 16 November 2020. EBITDA – Earnings before interest, taxes, depreciation and amortisation, share-based payment charge, impairment of goodwill, amortisation of acquired intangible assets, negative goodwill, loss/gain on disposal and transaction costs related to acquisitions as well as income from reversal of such costs and from unused amounts due for business acquisitions. catering and hospitality), particularly in France. The test can be used to evaluate the efficacy and safety of surgical masks and hygienic masks against COVID-19. In August 2020, Eurofins Technologies launched its GSD NovaPrime® RNA Extraction kits, which are reagents for automated extraction of genomic SARS-CoV-2 RNA (ribonucleic acid) from clinical swab samples. Eurofins Scientific, through its subsidiaries (hereinafter “Eurofins” or “the Group”), believes it is the global leader in food, environmental, pharmaceutical and cosmetics products testing and in agroscience CRO services. In August 2020, Eurofins Discovery expanded its chemistry capacity to serve customer demand in the growing market of outsourced drug discovery with a new building nearing completion at Eurofins Discovery’s flagship chemistry site at Eurofins Villapharma in Murcia, Spain. These APMs are described in more detail in the Condensed Interim Consolidated Financial Statements for the period ended 30 June 2020 in Note 1 and in the Consolidated Financial Statements 2019 in Notes 1.27 and 1.28. France +33 1707 507 18 Q1 2020: Group net income of EUR 223m impacted by EUR 313m corona-related claims Q1 2020 Results, 7 May 2020 2020 Group net income outlook withdrawn on 21 April due to uncertain environment Group net income of EUR 223m (-5.1%) –Group RoE at 9.0%, above minimum target GWP grow by 6.4% (curr.-adj. In October 2020, Eurofins’ Expertise Centre for Complex Carbohydrates & Chemistry (CCC) announced the development and availability of a new method for the identification of fructans in infant formula and adult nutritionals matrices. Careers |  Food service, restaurants, hospitality, travel and activities requiring on-site sampling or patient’s enrolment for clinical trials still see many restrictions in several countries and thus continued to require less testing services than usual in Q3 2020. By having significantly contributed to develop and validate internationally a method that now has received the official standard status by AOAC, ISO and IDF, the Eurofins CCC demonstrates Eurofins’ commitment to providing high quality test methods for its food industry customers. Some developments that have taken place since the Group reported its H1 2020 results are highlighted below. In the Rest of the World, Food, Environment and BioPharma testing services experienced a strong rebound across the Asia Pacific region with high single digit organic growth in Q3 2020 and above 5% in NM 2020. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. For 2022, achieve EUR 5.7bn revenues, including a 5% organic CAGR on the core non COVID-19 testing and reagents business from 2019 and EUR 100m from acquisitions (EUR 200m annual revenues consolidated at mid-year), EUR 1.35bn adjusted EBITDA and EUR 800m Free Cash Flow to the Firm. Share-based payment charge and acquisition-related expenses, net – Share-based payment charge, impairment of goodwill, amortisation of acquired intangible assets, loss/gain on disposal, negative goodwill and transaction costs related to acquisitions as well as income from reversal of such costs and from unused amounts due for business acquisitions. Terms and Conditions | Eurofins Global. For more information, please visit www.eurofins.com or contact: These new objectives assume that, by then, the lost growth of the non COVID-19 testing core business compared to the 5% objective in 2020 due to the lockdowns and travel restrictions will be caught back in full as was the case for the revenues lost due to the 2019 cyber-attack. Actual results may exceed these significantly, particularly in 2020, but this cannot be quantified at this time. It continues to expect to receive additional refunds over the coming months. Eurofins management is confident that the Group should be able to achieve or exceed these 2020-2022 objectives set as follows: For 2020, achieve EUR 5bn of revenues, including 5% from organic growth, EUR 1.1bn adjusted, For 2021, achieve EUR 5.45bn revenues, including 5% from organic growth, EUR 1.25bn adjusted EBITDA and EUR 700m. In September 2020, Eurofins Technologies announced that its ELISA assay (enzyme-linked immunosorbent assay) for the detection of aflatoxin M1, I’screen AFLA M1 milk, has been granted AOAC Research Institute Performance Tested Methods. It can also be used as part of surveillance testing. These state of the art standards can be used to maintain calibrations in most in-house testing equipment, and are recognized by major equipment manufacturers as the standards of choice. Cookie Notice | Disposals correspond to the sale by Eurofins of business assets to a third party. Eurofins provides in the Income Statement certain alternative performance measures (non-IFRS information such as “Adjusted Results2 and Separately Disclosed Items3”) that exclude certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Illustration of Eurofins’ 2020-2022 revenues objectives * Objectives include €150m from acquisitions in 2020 & 2021 and €200m in 2022 (€50m, €75m and €100m, revenues consolidated each year respectively). In addition, Eurofins shows the following measures: “Organic growth1” and “EBITDA4” with the objective to be close and consistent with the information used in internal Group reporting to measure the performance of Group companies and information published by other companies in the sector. Q1 2020 Results May 12, 2020. Beyond 2022, continued organic growth of at least 5% per annum and increasing margins and cash flows. Mature scope: excludes start-ups and acquisitions in significant restructuring. Eurofins Corporate Timetable, financial calendar, publication dates. The results were a blow-out. The Group is introducing 2022 objectives, as 2022 should hopefully be the first year where the pandemic is brought under control and without any COVID-19 related impact (neither positive nor negative). ... deliver excellent results, ... We are proud to be named one of the top 700 Diversity Leaders 2020 of 10 000 public and private European companies analysed by the Financial Times. This report may not be reproduced ... and Eurofins Lancaster Laboratories In August 2020, Eurofins became the … Eurofins scientists develop multiple new solutions to support the world’s fight against the COVID-19 pandemic – ramping up production to enable over 20 million patients tests per month by end May 2020 Activity shows strong resilience in Q1 2020 – April 28, 2020. By geography, Eurofins’ revenue growth for NM 2020 was 15.2% in Europe, 9.3% in North America and 3.8% in the Rest of the World, reflecting the different business exposures between regions and how those have been affected by the pandemic (Eurofins has limited Clinical Diagnostics and BioPharma testing activities in the Rest of the World). For more information, please refer to Note 3.18 of the Consolidated Financial Statements for the year ended 31 December 2019. • Net debt14 at the end of June 2020 decreased significantly to … Eurofins launches new tests and massive capacity for detecting and monitoring new variants of SARS-CoV-2, Eurofins GeneScan Technologies announces AOAC PTM accreditation for the VIRSeek SARS-CoV-2 detection workflow on environmental surfaces under the AOAC SARS-CoV-2 Emergency Response Validation Program, Eurofins Genomics launches cost-effective SARS-CoV-2 full-length viral genome sequencing services essential in the identification of viral mutations, Eurofins launches COVID-19 PCR tests with at-home self-sampling options in Europe and donates sequencing capacity to identify VUI-2020-12/01 strain reported to spread faster in the UK, Eurofins launches a rapid SARS-CoV-2 antigen test and a RT-PCR test in a self-sampled, gargling format, Eurofins U.S. Clinical Diagnostic Laboratories Partner with Insurance Providers to Cover FDA-Authorized At-Home COVID-19 Test, Eurofins launches sensitive, fast and cost-effective high throughput SARS-CoV-2 test kits for widely available Sanger sequencing equipment, Eurofins U.S. Clinical Diagnostics Network Receives EUA Approval of At Home COVID-19 Test At Home COVID-19 Nasal PCR Test is easy to use and painless, Eurofins Biomnis to create additional capacity of 15,000 tests per day carried out within 24 hours to help combat the second wave of the COVID-19 pandemic, Eurofins launches Europe’s first validated test method to evaluate filtration capacity of masks for SARS-CoV-2, Eurofins Diatherix launches Flu Plus to identify SARS-CoV-2 and five additional viruses, Eurofins Technologies Serological Assays Demonstrate Ability to Identify Neutralizing Antibodies, Eurofins providing COVID-19 analytical testing and services for Pennsylvania Long Term Care Facilities and vulnerable population citizens, Eurofins Clinical Diagnostics Launches Lower Cost Highly Accurate COVID-19 PCR Test, Eurofins Technologies launches reagents for automated extraction of genomic SARS-CoV-2 RNA from clinical swab samples, Eurofins publishes robust method to analyse SARS-CoV-2 in wastewater samples, providing early warning of potential COVID-19 outbreak at a given site, Eurofins publishes method for early detection of asymptomatic SARS-CoV-2 virus spreaders, that does not require human PCR clinical testing, Eurofins Technologies launches rapid point-of-care testing devices that identify exposure to COVID-19 in only 10 minutes, Eurofins U.S. Clinical Diagnostics Network Announces Launch of Highly Accurate, Cost Effective, COVID-19 Pooled PCR Test, Eurofins Technologies launches total antibody (IgG, IgA and IgM) detection ELISA assays to aid the rapid identification of persons who have been exposed to SARS-CoV-2 (COVID-19), Eurofins Launches Eurofins SAFER@WORK™: a Comprehensive Suite of Risk-Based COVID-19 Safety Solutions for Businesses, Eurofins Technologies launches multiplex Real-Time PCR assay for SARS-CoV-2 (coronavirus) pathogen detection, Eurofins scientists develop multiple new solutions to support the world’s fight against the COVID-19 pandemic – ramping up production to enable over 20 million patients tests per month by end May 2020 Activity shows strong resilience in Q1 2020, Eurofins Medical Device Testing commitment to support the safety and efficacy of devices used in the COVID-19 Crisis Response, Eurofins BioPharma Product Testing delivers vital COVID-19 testing for all drug modalities and supply chains, Eurofins Technologies launches multiple CE-IVD marked serologic products for the detection of antibodies in patients who have been exposed to SARS-CoV-2 (COVID-19), Eurofins Genomics launches “SARS-CoV-2 Full-length Genome Sequencing” service to support researchers globally in their fight against the COVID-19 pandemic and outbreak source tracing, Eurofins Genomics U.S. launches new SARS-CoV-2 plasmid DNA controls and increases its capacity to produce probes and primers, all of which being key components of SARS-CoV-2 RT-PCR testing, Eurofins Discovery Supports Critical COVID-19 Drug Discovery Research with Products and Accelerated Drug Discovery Services, Eurofins Technologies launches multiple new products for the serologic detection of antibodies in patients who have been exposed to COVID-19, Gold Standard Diagnostics COVID-19 Antibody Tests Now Available, Viracor Eurofins Receives Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its SARS-CoV-2 RT-PCR laboratory-developed test (LDT), The National Kidney Registry and Viracor Eurofins Announce Coronavirus Antibody Testing for Donors and Recipients, Eurofins Scientific Offers a full range of Testing services for Personal Protective Equipment (PPEs) and Medical Devices used in the fight against the COVID pandemic, Eurofins’ U.S. Clinical Diagnostics Network Launches Coronavirus (COVID-19) Antibody Testing, Announcing Labs@HOME, an In-Home Mobile Phlebotomy Blood Draw Service for Post-Transplant Patient Testing During COVID-19, Eurofins Technologies launches testing solutions for the detection of SARS-CoV-2 on environmental surfaces, Eurofins Scientific Supports Healthcare Authorities in Europe, the U.S.A. and Brazil in their Fight against the COVID-19 Pandemic with Additional Testing Options and Fast Growing Capacity, Eurofins Transplant Genomics and Viracor Will Partner to Offer Remote Sample Collection Options to Support Care for Kidney Transplant Recipients During COVID-19 Outbreak, Diatherix Eurofins launches SARS-CoV-2 virus identification for the COVID-19 respiratory infection, Eurofins Scientific Supports SARS-CoV-2 Analyses needs in the U.S.A. and in Europe with Multiple Testing Options, Viracor Eurofins Launches Coronavirus SARS-CoV-2 RT-PCR Test with Same Day Results (12-18 Hours), Homepage | 

Mondial Car Jumet, Marteau Traduction Anglais, L'hébreu Et L'araméen Sont Des Langues, Paris Joinville Football, Chanson Lalala 2020, Pièce De Théâtre De Boulevard, J'ai Pas Compris, Marius Colucci Fils De Coluche,